| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H31N5O3S |
| Molecular Weight | 421.557 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N=C(CS(C)(=O)=O)N=C1NCCCOC2=CC=CC(CN3CCCCC3)=C2
InChI
InChIKey=JEYKZWRXDALMNG-UHFFFAOYSA-N
InChI=1S/C20H31N5O3S/c1-24-20(22-19(23-24)16-29(2,26)27)21-10-7-13-28-18-9-6-8-17(14-18)15-25-11-4-3-5-12-25/h6,8-9,14H,3-5,7,10-13,15-16H2,1-2H3,(H,21,22,23)
| Molecular Formula | C20H31N5O3S |
| Molecular Weight | 421.557 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sufotidine is a triazolamine derivative patented by Glaxo Group Ltd. as long-acting histamine H2-blocker useful for the treatment of peptic ulceration and oesophagitis. In phase II clinical treatment with sufotidine decreases median integrated 24-hour intragastric acidity by 95% compared with placebo. Twice daily sufotidine maintained the pH above 3 throughout the 24 h. Unfortunately, no further development report has been published and it seems, that Sufotidine development currently discontinued.
